Rosebud Biosciences develops targeted therapies for rare pediatric genetic diseases using patient-specific organoid models. The company engineers micropatterned 2.5D organoids from induced pluripotent stem cells that replicate individual genetic mutations for drug screening. This platform enables the high-throughput testing of small molecules, gene therapies, and RNA therapeutics against complex developmental disorders.
Funding
Funding not disclosed
Founders
Product
Problem
The vast majority of rare genetic diseases affecting children lack approved treatments, resulting in high mortality rates and limited options for affected families. Traditional drug development methods are often slow, costly, and ineffective for these unique conditions due to the difficulty of replicating the specific genetic mutations in preclinical models.
Solution
Rosebud Biosciences develops targeted therapies for rare genetic diseases in children using a proprietary organoid platform. The company creates in-vitro organoids that precisely replicate a child's specific genetic mutation, enabling rapid and accurate drug screening. By modeling human development in a dish, Rosebud Biosciences can monitor organoid development and disease progression, and identify potential therapeutic interventions. Their platform leverages robotics and machine learning to scale up drug discovery and accelerate the identification of effective cures for previously untreatable conditions.
Target Audience
The primary target audience includes pharmaceutical companies seeking partners for heart, liver, neural, or kidney disease drug therapies, as well as families affected by rare genetic diseases.
Features
- Disease modeling using micropatterned organoids derived from patient-specific human induced Pluripotent Stem Cells (hiPSCs)
- Organoids contain multiple cell lineages without complex biopolymer matrices or specialized tissue culture
- Longitudinal monitoring of organoid development via live cell brightfield microscopy, biomarker monitoring, and calcium assays
- Automated drug screening platform capable of simultaneously monitoring up to 10,000 organoids
- Machine learning models for automated detection of disease phenotypes in organoids
- Robotics and specific protocols to differentiate tissue- and disease-specific organoids under standardized conditions